The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog

Neuropsychopharmacology

Volumn 34, Issue 8, 2009, Pages 2011-2018

  Feifel, D ^a   Mexal, S ^b   Melendez, Gilia ^a   Liu, Philip Y T ^a   Goldenberg, Joseph R ^a   Shilling, Paul D ^a  

^a UCSD MEDICAL CENTER   (United States)

^b Cenomed BioSciences   (United States)

Author keywords

Animal model; Brattleboro rat; Cognitive deficit; Neurotensin; Schizophrenia; Social discrimination

Indexed keywords

CLOZAPINE; NEUROTENSIN 1 AGONIST; NEUROTENSIN DERIVATIVE; PD 149163; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRATTLEBORO RAT; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; EXPLORATORY BEHAVIOR; GENETIC MODEL; MALE; MEMORY DISORDER; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL DISCRIMINATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; MALE; MENTAL DISORDERS; NEUROTENSIN; RATS; RATS, BRATTLEBORO; RATS, LONG-EVANS; RECEPTORS, NEUROTENSIN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR;

EID: 67449126865     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.15     Document Type: Article

References (49)

1. Agid O, Kapur S, Warrington L, Loebel A, Siu C (2008). Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res 102: 241-248.
2. Agid O, Seeman P, Kapur S (2006). The 'delayed onset' of antipsychotic action - an idea whose time has come and gone. J Psychiatr Neurosci 31: 93-100.
3. Azmi N, Norman C, Spicer CH, Bennett GW (2006). Effects of a neurotensin analogue (PD149163) and antagonist (SR142948A) on the scopolamine-induced deficits in a novel object discrimination task. Behav Pharmacol 17: 357-362.
4. Banks WA, Wustrow DJ, Cody WL, Davis MD, Kastin AJ (1995). Permeability of the blood-brain barrier to the neurotensin 8-13 analog NT1. Brain Res 695: 59-63.
5. Becker A, Grecksch G (2006). Pharmacological treatment to augment hole board habituation in prenatal vitamin D-deficient rats. Behav Brain Res 166: 177-183.
6. Bespalov A, Jongen-Rêlo AL, van Gaalen M, Harich S, Schoemaker H, Gross G (2007). Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. J Pharmacol Exp Ther 320: 944-950.
7. Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ (2004). Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin Via receptor knockout mice. Neuropsychopharmacology 29: 483-493.
8. Birkett SD, Pickering BT (1988). The vasopressin precursor in the Brattleboro (di/di) rat. Int J Pept Protein Res 32: 565-572.
9. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC et al (2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 31: 5-19.
10. Dunn MJ, Killcross S (2006). Differential attenuation of damphetamine-induced disruption of conditional discrimination performance by dopamine and serotonin antagonists. Psychopharmacology 188: 183-192.
11. Engelmann M, Landgraf R (1994). Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats. Physiol Behav 55: 145-149.
12. Engelmann M, Wotjak CT, Landgraf R (1995). Social discrimination procedure: an alternative method to investigate juvenile recognition abilities in rats. Physiol Behav 58: 315-321.
13. Feifel D, Melendez G, Priebe K, Shilling PD (2007). The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav Brain Res 181: 278-286.
14. Feifel D, Melendez G, Shilling PD (2003). A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist. Neuropsychopharmacology 28: 651-653.
15. Feifel D, Melendez G, Shilling PD (2004). Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not Haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology 29: 731-738.
16. Feifel D, Priebe K (2001). Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol. Biol Psychiatry 50: 425-433.
17. Feifel D, Reza TL, Wustrow DJ, Davis MD (1999). Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther 288: 710-713.
18. Floresco SB, Geyer MA, Gold LH, Grace AA (2005). Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull 31: 888-894.
19. Gold JM (2004). Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 72: 21-28.
20. Grayson B, Idris NF, Neill JC (2007). Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184: 31-38.
21. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I et al (2004). First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 66: 125-135.
22. Green MF (2006). Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 67: e12.
23. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff? Schizophr Bull 26: 119-136.
24. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA et al (2002). The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 51: 972-978.
25. Grimond-Billa SK, Norman C, Bennet GW, Cassaday HJ (2008). Selectively increased trace conditioning under the neurotensin agonist PD 149163 149163 in an aversive procedure in which SR 142948A was without intrinsic effect. J Psychopharmacol 22: 290-299.
26. Hagan JJ, Jones DN (2005). Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull 31: 830-853.
27. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M (2005). Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 162: 1888-1895.
28. Jentsch JD, Arguello PA, Anzivino LA (2003). Null mutation of the arginine-vasopressin gene in rats slows attentional engagement and facilitates response accuracy in a lateralized reaction time task. Neuropsychopharmacology 28: 1597-1605.
29. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A (2006). One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 81: 1-15.
30. Kinkead B, Nemeroff CB (2006). Novel treatments of schizophrenia: targeting the neurotensin system. CNS Neurol Disord Drug Targets 5: 205-218.
31. Laycock JF, Gartside IB, Chapman JT (1983). A comparison of the learning abilities of Brattleboro rats with hereditary diabetes insipidus and Long-Evans rats using positively reinforced operant conditioning. Prog Brain Res 60: 183-187.
32. Lublin H, Eberhard J, Levander S (2005). Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 20: 183-198.
33. Medalia A, Gold J, Merriam A (1988). The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 3: 249-271.
34. Mishara AL, Goldberg TE (2004). A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55: 1013-1022.
35. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H et al (2008). Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D(1) and serotonin 5-HT (IA) receptors. Psychopharmacology 202: 315-328.
36. Norman C, Grimond-Billa S, Bennett G, Cassaday H (2008). A neurotensin agonist and antagonist decrease and increase activity, respectively, but do not preclude discrete cue conditioning. J Psychopharmacology 2008 (E-pub).
37. Petrie KA, Bubser M, Casey CD, Davis MD, Roth BL, Deutch AY (2004). The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat. Neuropsychopharmacology 29: 1878-1888.
38. Remillard S, Pourcher E, Cohen H (2005). The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophr Res 80: 99-106.
39. Rollnik JD, Borsutzky M, Huber TJ, Mogk H, Seifert J, Emrich HM et al (2002). Short-term cognitive improvement in schizophrenics treated with typical and atypical neuroleptics. Neuropsychobiology 45: 74-80.
40. Shilling PD, Kinkead B, Murray T, Melendez G, Nemeroff CB, Feifel D (2006). Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits. Biol Psychiatry 60: 1278-1281.
41. Southam E, Cilia J, Gartlon JE, Woolley ML, Lacroix LP, Jennings CA et al (2009). Preclinical investigations into the antipsychotic potential of the novel histamine H (3) receptor antagonist GSK207040. Psychopharmacology 201: 483-494.
42. Stip E, Chouinard S, Boulay LJ (2005). On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29: 219-232.
43. Terranova JP, Chabot C, Barnouin MC, Perrault G, Depoortere R, Griebel G et al (2005). SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology (Berl) 181: 134-144.
44. Wersinger SR, Kelliher KR, Zufall F, Lolait SJ, O'Carroll AM, Young III WS (2004). Social motivation is reduced in vasopressin lb receptor null mice despite normal performance in an olfactory discrimination task. Horm Behav 46: 638-645.
45. Wiley JL (2008). Antipsychotic-induced suppression of locomotion in juvenile, adolescent and adult rats. Eur J Pharmacol 578: 216-221.
46. Williams AR, Carey RJ, Miller M (1983). Behavioral differences between vasopressin-deficient (Brattleboro) and normal Long-Evans rats. Peptides 4: 711-716.
47. Williams AR, Carey RJ, Miller M (1985). Altered emotionality of the vasopressin-deficient Brattleboro rat. Peptides 6(Suppl 1): 69-76.
48. Winslow JT, Insel TR (2002). The social deficits of the oxytocin knockout mouse. Neuropeptides 36: 221-229.
49. Woodward ND, Purdon SE, Meltzer HY, ZaId DH (2005). A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8: 457-472.